Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04735796 · ClinicalTrials.gov registry record · Phase 1
Study of LM-102 in Subjects in Advanced Tumors
A Phase 1 study, sponsored by LaNova Medicines Limited.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04735796 is a Phase 1 study that was terminated before completion, run by LaNova Medicines Limited. The registered enrollment target is 9 participants.
The verdict
NCT04735796, a Phase 1 study, was terminated before completion, sponsored by LaNova Medicines Limited.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a phase Ⅰ, first-in-human, open-label, dose escalation study to evaluate the safety and tolerability, PK, immunogenicity and preliminary anti-tumor activity of LM-102 injection in subjects with CLDN18.2-positive advanced solid tumors.
Interventions
- DRUG Drug：LM-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-05-27 |
| Est. Completion | 2022-05-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04735796
The ClinicalTrials.gov registry entry for NCT04735796 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LaNova Medicines Limited, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Drug：LM-102 is the first listed.
NCT04735796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04735796 about?
NCT04735796 is a clinical study titled "Study of LM-102 in Subjects in Advanced Tumors". This is a phase Ⅰ, first-in-human, open-label, dose escalation study to evaluate the safety and tolerability, PK, immunogenicity and preliminary anti-tumor activity of LM-102 injection in subjects with CLDN18.2-positive advanced solid tumors.
What is the current status of trial NCT04735796?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2021-05-27. Estimated completion is 2022-05-19.
What interventions are being tested in trial NCT04735796?
The interventions under investigation include: Drug：LM-102 (DRUG).
Who is sponsoring clinical trial NCT04735796?
This trial is sponsored by LaNova Medicines Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.